Regarding the cardiac issue, recent studies have demonstrated that TFAM inhibits the NFAT4-MMP9 proteolytic pathway in TFAM transgenic mice subjected to aorticbanding-induced heart failure, reducing pathological cardiac remodeling like hypertrophy and other HF associated factors. Here, NFATC3 is linked to hypertrophy.